Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections

Clênio Silva Cruz, Mayra Fernanda Ricci*† and Angélica Thomaz Vieira*†

Laboratory of Microbiota and Immunomodulation (LMI), Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive metabolites and antimicrobial molecules, and regulating the immune and inflammatory responses. Imbalance in the abundance, diversity, and function of the gut microbiota (known as dysbiosis) have been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut-lung axis. Hence, the use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system. This review discusses the role and responses of probiotics, prebiotics, and synbiotics in the gut-lung axis in the face of lung infections.

Keywords: symbiotics, mucosal immunity, gut-lung axis, prebiotics, probiotics, immunobiotics, inflammation, microbiota

INTRODUCTION

Microorganisms and humans have co-evolved for thousands of years, and many survival functions have been defined throughout this time for both. All body surfaces are colonized by complex and dynamic communities of symbiotic microorganisms, including bacteria, viruses, fungi, helminths, and protists, called microbiota (Grice and Segre, 2012; Sender et al., 2016). As demonstrated by next-generation sequencing, the lungs and gut possess unique microbiota that differ mainly in composition and structure, with bacteria being the most predominant microorganisms (Dickson et al., 2015; Santacroce et al., 2020). The microbiota plays fundamental roles in host homeostasis via the metabolism of nutrients, production of vitamins, metabolites, and antimicrobial molecules, activation of the immune system, and regulation of the inflammatory process (Dang and Marsland, 2019). The gut dysbiosis has been shown to increase susceptibility to infection in the lungs, and infections in the lung are identified as a cause of gut dysbiosis; highlighting a bidirectional link between these two organs; this crosstalk is now called the gut-lung axis (Li et al., 2008; Hand et al., 2016; Budden et al., 2017; Sencio et al., 2020). Also, the lung and gut originate from the same embryonic organ, the foregut, and consequently have some structural similarities that might...
contribute to the interaction between these two organs (Faure and de Santa Barbara, 2011). Respiratory tract infections (RTI) are a global health concern. Approximately 2.38 million deaths were attributed to RTI in 2016 alone, making it the sixth leading cause of mortality among all ages and the leading cause of death among children under 5 years (Ferkol and Schraufnagel, 2014; Troeger et al., 2018). Given the importance of the gut-lung axis, our review summarized the latest experimental and clinical studies on this topic and showed that modulation of the gut-lung axis with probiotics, prebiotics, and synbiotics, could be an important therapeutic target for preventing and treating lung infections caused by bacteria, viruses, fungi, and parasites.

GUT-LUNG AXIS IN RESPIRATORY TRACT INFECTIONS

The respiratory system is composed of different organs, and is divided into two main parts: the upper respiratory tract (URT) and the lower respiratory tract (LRT). The URT comprises the nostrils, nasal passages, paranasal sinuses, nasopharynx, and oropharynx, while the lower respiratory tract comprises the trachea, bronchi, bronchioles, and alveoli. These organs make up one of the largest surface areas in the human body, that from the nostrils to the lungs, is colonized by a symbiotic and diverse community of microorganisms (Figure 1).

The microbiota of the lungs and gut of healthy individuals differ significantly in taxonomic composition, diversity, and function. In contrast to the thriving resident microbiota in the gut, the lung microbiota is composed of transient microorganisms mainly derived from URT. While Bacteroidetes and Firmicutes are the most abundant bacterial phyla in both microbiotas, the lung and gut microbiota are very different at the species level. In the lungs, the genera Streptococcus spp., Veillonella spp., and Prevotella were the most abundant, whereas Bacteroides, Faecalibacterium, and Bifidobacterium are more prevalent in the gut (Sender et al., 2016). In a disease or dysbiotic state, other organisms are present in the lung, such as viruses, including human rhinovirus, human bocavirus, polyomaviruses, human adenovirus, and human coronavirus, and fungi such as Aspergillus spp., Penicillium spp., Candida spp., and Alternaria spp. (Papadopoulos and Skevaki, 2006; Limon et al., 2017).
The immune responses in the gut-lung axis depend on the balance of microbiota composition, particularly in the gut. The regulated interaction between the metabolites and antigens of symbiotic microbiota with the host is crucial for the activation of pattern recognition receptors (PRRs) and metabolic sensor receptors such as G-protein-coupled receptors (GPCRs), and the production of inflammatory mediators, which are necessary for the migration, activation, and proliferation of innate and adaptive immune cells responsible for the production of pro-and anti-inflammatory cytokines, immunoglobulins, and antimicrobial peptides (Fan and Pedersen, 2021). These cells and molecules can move bidirectionally between the lungs and the gut through the bloodstream and lymphatic system and regulate immune and inflammatory responses (Marsland et al., 2015; Dang and Marsland, 2019).

Intestinal dysbiosis is responsible for increasing the susceptibility of the host to lung disease, as evidenced by the high prevalence of asthma in patients with irritable bowel syndrome (Yazar et al., 2001). Experimentally, mice treated with antibiotics are more susceptible to lethal infection by the influenza virus (IFV) (Ichinohe et al., 2011; Pang et al., 2018). Furthermore, infections in the lungs are also linked to dysbiosis in the gut; mice infected with IFV displayed a significant increase in Enterobacteriaceae and decreased diversity of Lactobacillus and Lactococcus (Wang et al., 2018). Influenza infection also affects the production of short-chain fatty acids (SCFAs) and impairs the gut barrier properties thereby increasing susceptibility to second bacterial infections (Sencio et al., 2020, 2021).

SCFAs, such as butyrate, propionate, and acetate derived from the fermentation of dietary fibers by the microbiota, are involved in regulating the inflammatory process and pulmonary immune response (Fukuda et al., 2011; Trompette et al., 2014). SCFAs activate GPCRs and inhibit histone deacetylases, thus contributing to the reduction of inflammation in the gut-lung axis by inhibiting the NF-κB signaling pathway, increasing regulatory T (Treg) cells, and decreasing T helper 1 (Th1) and Th17 cells (Maslowski et al., 2009; Kim et al., 2013; Li et al., 2018). SCFAs can also reach the bone marrow and influence the development and generation of immune cells such as Ly6C- and Ly6C+ monocytes and dendritic cells, which can be recruited into the lungs and modulate the immune response against pathogens (Trompette et al., 2014, 2018; Kopf et al., 2015).

Our research group has also demonstrated that activation of the GPR43 receptor in neutrophils and alveolar macrophages by acetate is essential for modulating the inflammatory response and controlling pulmonary infection by Klebsiella pneumoniae (Galvão et al., 2018) and Streptococcus pneumoniae serotype 1 in mice (Sencio et al., 2020). In another study, activation of GPR43 in pulmonary epithelial cells induced interferon (IFN)-β in the lungs and increased the protection of mice infected with respiratory syncytial virus (RSV) (Antunes et al., 2019).

**PROBIOTICS, PREBIOTICS, AND SYNBIOITICS**

Probiotics are live microorganisms that confer benefits to the host when administered in adequate amounts (Salminen et al., 2021). Probiotics are considered important tools for the modulation of microbiota in the gut-lung axis, with their benefits on the gut-lung axis dependent on the strains used (Figure 2). However, common mechanisms have been reported between species, such as 1) colonization of the respiratory and intestinal tracts, 2) production of SCFAs and antimicrobial peptides, 3) maintenance of the integrity of the intestinal and pulmonary mucosa, and 4) stimulation of the innate and adaptive immune system (Bermúdez-Brito et al., 2012; Salminen et al., 2021). The benefits of probiotics have been shown in animal models and clinical studies in many disease conditions, such as post-antibiotic-associated diarrhea, allergies and inflammatory bowel diseases, and respiratory tract infections (Vieira et al., 2013). For a given microorganism to be assessed as a probiotic, biosafety criteria and scientific evidence regarding its biological benefits must be considered (Harzallah and Belhadj, 2013). Lactobacillus and Bifidobacterium species are more commonly used as probiotics; however, yeasts, certain Streptococcus spp. strains, and Bacillus spp. are also used as probiotics, but less frequently (Fijan, 2014). The use of inactivated probiotics is also of great interest because live probiotic microorganisms may cause systemic infections, excessive immune stimulation, and antibiotic resistance gene transfer (Doron and Snydman, 2015). Taking this into consideration, the term postbiotics was proposed as preparation for inanimate microorganisms and/or their components that confer a health benefit on the host (Salminen et al., 2021).

Prebiotics are dietary fibers, such as inulin, fructooligosaccharides, and galactooligosaccharides, which are fermented in the gut and promote an increase in the diversity and activity of specific symbiotic microorganisms (Salminen et al., 2021). The activity of prebiotics also leads to an enhancement of immune response, decrease in colon pH, local induction of reactive oxygen species (ROS), trophic effects on enterocytes, and anti-inflammatory responses (Vieira et al., 2013). In addition, the SCFAs butyrate and propionate, derived from the metabolism of prebiotics, can increase miRNAs through the inhibition of histone deacetylases, leading to improved antibody class switching and local and systematic impact on the T-dependent and T-independent immunoglobulin production (Sanchez et al., 2020).

Symbiotics consist of probiotics and prebiotics to achieve synergistic and complementary effects on their functions (Salminen et al., 2021). A recent meta-analysis of randomized controlled clinical trials involving over 10,000 individuals showed the effectiveness of symbiotic interventions in reducing the rate of respiratory tract infections (Chan et al., 2021). Understanding the specific mechanisms of interaction between probiotics and prebiotics and their modulation of the gut environment and immune response will lead to better utilization of the symbiotics to treat infections and metabolic diseases.

**Gut-Lung Axis Modulation in the Context of Bacterial Lung Infections**

The lung is highly vulnerable to bacterial infections due its constant exposure to environment agents. One of the most
common diseases caused by bacteria in the lungs is pneumonia that is characterized by alveolar infection and intense inflammatory response that ranges from mild to severe and can affect both the right and left lobes and may impair the gaseous exchange. The most common causes of bacterial pneumonia in immunocompetent hosts include *S. pneumoniae*, *Haemophilus* spp., and *Mycobacterium tuberculosis*. In immunocompromised hosts the number of pathogens that cause pneumonia is much larger, and in general those individuals are more vulnerable and have worse outcomes (van der Poll and Opal, 2009) (Table 1).

Several studies have shown that the oral administration of different strains of probiotics, such as *Lactobacillus bulgaricus* CRL 423 and *Streptococcus thermophilus* CRL 412 (Villena et al., 2006), *L. casei* CRL 431 (Villena et al., 2005, 2009), *L. fermentum* (Cangemi De Gutierrez et al., 2001), and *L. rhamnosus* CRL 1505 (Barbieri et al., 2017) causes: 1) increased resistance to infection, 2) decreased number of bacteria in the lungs, and 3) increased survival of mice infected with *S. pneumoniae*. In general, these articles, associated this protection with an increase in neutrophils, lymphocytes, macrophages, phagocytic activity, and levels specific anti-*S. pneumoniae* IgG and IgA antibodies to these pathogens. The increase in phagocytic activity and the number of neutrophils in the lower respiratory tract is the first line of defense against invading pathogens, and the increase in regulatory cells and cytokines contributes to the reduction of the inflammatory response.
| Strategy for microbiota modulation | Dose and route of administration | Experimental model | Pathogen | Main outcomes | References |
|-----------------------------------|--------------------------------|-------------------|----------|---------------|------------|
| **Effects on bacterial pathogen**  |                                |                   |          |               |            |
| *Lactobacillus bulgaricus* CRL 423 and *Streptococcus thermophilus* CRL 412 | $2 \times 10^8$ CFU, via oral Malnourished, Swiss albino mice | *Streptococcus pneumoniae* | Reduced bacterial load in the lungs; increased bactericidal function of bronco-alveolar phagocytes; reduced tissue inflammation; increased neutrophils in blood; and increased level of lung anti-pneumococcal IgA and IgG | Villena et al. (2006) |
| *Lactobacillus casei* CRL 431 | $1 \times 10^9$ CFU, via intranasal Malnourished, Male, 3-week-old Swiss albino mice | *Streptococcus pneumoniae* | Increased pathogen clearance from blood; lower lung damage; improved number of leukocytes and neutrophils; and increased levels of antipneumococcal IgA in BAL | Villena et al. (2009) |
| *Lactobacillus casei* CRL 431 | $1 \times 10^9$ CFU, via oral Male 6-week-old Swiss albino mice | *Streptococcus pneumoniae* | Increased pathogen clearance from blood; lower lung damage; improved number of leukocytes and neutrophils; and increased levels of antipneumococcal IgA in BAL | Villena et al. (2005) |
| *Lactobacillus fermentum* | $1 \times 10^7$, via intranasal Adult, BALB/c mice | *Streptococcus pneumoniae* | Increased the number of activated macrophages and lymphocytes; and increased anti-S.pneumoniae antibodies | Cangemi De Gutierrez et al. (2001) |
| *Lactobacillus rhamnosus* CRL1505 | $1 \times 10^9$ CFU, via intranasal Malnourished, Male, 3-week-old Swiss albino mice | *Streptococcus pneumoniae* | Enhanced lung clearance of P. aeruginosa; increased phagocytic activity of alveolar macrophages; and increased IgA and IgM levels in BAL | Barbieri et al. (2017) |
| *Lactobacillus casei* CRL 431, *Lactobacillus delbrueckii subsp. bulgaricus* and *Streptococcus thermophilus* | $1 \times 10^9$ CFU, via oral 3-week-old, Swiss albino mice | *Pseudomonas aeruginosa* | Decreased secretion in BAL of IL-6 and TNF-α | Alvarez et al. (2001) |
| *Lactobacillus rhamnosus* GG | $9 \times 10^8$ CFU, via intratracheal 6 to 8-week-old, FVB/N mice | *Pseudomonas aeruginosa* | Decreased secretion in BAL of IL-6 and TNF-α | Fangou et al. (2019) |
| *Biﬁdobacterium longum* 51A | $1 \times 10^8$, via oral 8 to 12-week-old, C57BL/6 WT and Mal/TIRAP-/- mice | *Klebsiella pneumoniae* | Reduced bacterial burden; faster resolution of inflammation; decreased lung damage; increased production of IL-10; and increased alveolar macrophages ROS associated with Mal/TIRAP activation | Vieira et al. (2016) |
| **Effects on viral pathogen** |                                |                   |          |               |            |
| *Lactobacillus casei* Shirota | $1 \times 10^8$ CFU, via oral Neonatal and infant, BALB/c mice | Influenza A/PR/8/34 (H1N1) | Higher survival rate, reduced titer of virus in the nasal washings; greater pulmonary NK cell activity; and increased IL-12 production by mediastinal lymph nodes | Yasui et al. (2004) |
| *Lactobacillus rhamnosus* M21 | $1 \times 10^9$ CFU, via oral Female, specific pathogen-free, BALB/c mice | Influenza A/NWS/33 (H1N1) | Increased IL-2 and IFN-γ; increased IgA levels; reduced inflammatory cells in BAL | Song et al. (2016) |
**TABLE 1** | (Continued) Pre-clinical studies on the modulation of the microbiota for treatment of bacterial and viral lung infections.

| Strategy for microbiota modulation | Dose and route of administration | Experimental model | Pathogen | Main outcomes | References |
|-----------------------------------|---------------------------------|--------------------|----------|---------------|------------|
| **Lactobacillus pentosus S-PT84** | Heat-killed *L. pentosus S-PT84*, via intranasal | Female, BALB/c mice | Influenza A/PR/8/34 (H1N1) | Increased survival rates; reduced titer of influenza virus in BAL; increased IL-12 and IFN-γ production in mediastinal lymph node cells; increased IL-12 and IFN-γ in BAL; and increased NK cell activity | Izumo et al. (2010) |
| **Lactobacillus plantarum and Leuconostoc mesenteroides** | $1 \times 10^5$ CFU, via oral | Female, 5-week-old, BALB/c mice | Influenza rK09 (H1N1) | Restricted viral replication; and increased rates of survival of infected mice | Bae et al. (2018) |
| **Lactobacillus rhamnosus GG** | 200 μg of *L. rhamnosus GG* lyophilized, via intranasal | Female, 7-week-old BALB/c mice | Influenza A/PR/8/34 (H1N1) | Higher survival rate; increased cell-killing activity of lung cells; and increased mRNA expression of interleukin IL-1 beta, TNF and MCP-1 | Harata et al. (2013) |
| **Lactobacillus acidophilus L-92** | $4 \times 10^{10}$ CFU, via oral | Female, 4-weeks-old BALB/c mice | Influenza A/PR/8/34 (H1N1) | Reduced Virus titers in the lung; increased NK cells activity; decreased the number of neutrophils; increased eotaxin, MCSF, IL-1β, RANTES and IFN-α in the lung; and increased IL-17 levels in Peyer’s patches | Goto et al. (2013) |
| **Lactobacillus plantarum DK119** | $1 \times 10^5$ or $1 \times 10^6$ CFU, via oral | Female, BALB/c mice | Influenza A/PR8 | Reduced lung viral loads; increased levels of cytokines IL-12 and IFN-γ in BAL; and reduced degree of inflammation | Park et al. (2013) |
| **Lactococcus lactis subsp. lactis JCM8505** | 1 mg of heat-killed *L. lactis subsp. lactis JCM8505*, via oral | Female, DBA/2j mice | Murine Parainfluenza virus (mPIV1) | Increased survival rate; prevention of weight loss; reduced lung histopathology scores; increased activation of Peyer’s patches (PP) and PP pDCs; increased levels of type I IFNs; and increased expressions of anti-viral factors such as Isg15, Gass2, and Viperin at lung | Jounai et al. (2015) |
| **Lactobacillus paracasei CNCM I-1518** | $2 \times 10^5$ CFU, via oral | Female, 6-week-old BALB/c mice | Influenza A/Scotland/20/74 (H3N2) | Reduced weight loss; and increased recruitment of inflammatory myeloid cells, such as interstitial monocytes and dendritic cells, to the lungs | Belkacem et al. (2017) |
| **Bacillus subtilis 3 (UCM B-5007)** | $1 \times 10^4$ CFU, via oral | Four-week-old BALB/c mice | Influenza A/FM/1/47 (H1N1) | Reduced lung immune-coagulative reaction triggered by TLR3 activation | Starosila et al. (2017) |
| **Lactobacillus rhamnosus CRL1505** | $1 \times 10^5$ CFU, via oral | Male, 6-week-old BALB/c mice | Respiratory Syncytial Virus strain A2 and Influenza virus A/PR8/34 (H1N1) | Protection against lethal infection; reduced granulocyte recruitment; reduced expression of proinflammatory cytokines CXCL10, CXCL1, CCL2, and TNF; Increased levels of IFN-α, IFN-β, IFN-γ, IL-6 and IL-10; increased levels of CD4+ Tregg cells and CD11c+‘CD103+’ DCs; reduced viral replication and lung damage | Gąbrowszewska et al. (2011) |
| **Lactobacillus rhamnosus CRL1505 and CRL1506** | $1 \times 10^5$ CFU, via intranasal | Female, 3-week-old BALB/c mice | Human RSV strain A | Similar results were observed in mice infected with *Pseudomonas aeruginosa*, treated orally with the probiotics *L. casei CRL 431*, *L. delbrueckii* subsp. *bulgaricus*, *S. thermophilus* (Alvarez et al., 2001) and *L. rhamnosus* GG (Meiertz et al., 2013). | Tomosada et al. (2013) |

Response and to the maintenance of tolerance to symbiotic microorganisms, which is necessary to reduce damage associated with infections by pathogens (Martin and Frevert, 2005).
### TABLE 2 | Clinical studies on the modulation of the microbiota for treatment of bacterial and viral lung infections.

| Strategy for microbiota modulation | Dose and route of administration | Study design and subjective | Pathogen and disease | Outcome | References |
|-----------------------------------|---------------------------------|----------------------------|---------------------|---------|------------|
| **Effects on bacterial pathogen**  |                                 |                            |                     |         |            |
| Lactobacillus casei rhamnosus Lcr35 | $1 \times 10^9$ CFU, via oral | Prospective, randomized, double-blind, placebo-controlled pilot study with patients aged 18-91 | Pseudomonas aeruginosa | Reduction in the occurrence of $P.~aeruginosa$ respiratory colonization and/or infection in the probiotic group. Reduction in the frequency of VAP to $P.~aeruginosa$ | Forestier et al. (2008) |
| Lactobacillus rhamnosus GG | $2 \times 10^9$ CFU, via oral | Prospective, randomized, double-blind, placebo-controlled trial with patients at high risk of developing VAP | VAP by Gram-positive and Gram-negative pathogens | Reduction in the development of microbiologically confirmed VAP. Patients treated with probiotics had fewer days of antibiotics prescribed for VAP. | Morrow et al. (2010) |
| Bifidobacterium breve Yakult, Lactobacillus casei Shirota, and galacto-oligosaccharide | $1 \times 10^6$ CFU of B. breve and L. casei and Galacto-oligosaccharides in a 10 g/day formula, via oral | Randomized controlled trial with patients with more than 16 years old | Patients with more than 16 years old, placed on a ventilator, and who were diagnosed as having sepsis | Reduced incidence of VAP. Increased number of Bifidobacterium and Lactobacillus. Increased concentration of acetate in the feces | Shimizu et al. (2018) |
| **Effects on viral pathogens** |                                 |                            |                     |         |            |
| Lactobacillus rhamnosus GG | $1 \times 10^9$ CFU/day | Randomized, double-blind, placebo-controlled study with preterm infants | Rhinovirus-associated respiratory tract infection | Reduced respiratory tract infections. Reduced rhinovirus-induced episodes | Luoto et al. (2014) |
| ATCC 5310 and galacto-oligosaccharide and polydextrose mixture | $1-30$ days and $2 \times 10^9$ CFU/day | Open-label, parallel-group trial with elementary schoolchildren | Influenza infection | Reduced incidence of influenza infections | Waki et al. (2014) |
| Lactobacillus brevis KB290 | $6 \times 10^7$, via oral | Randomized, double-blind, placebo-controlled study with nursing home residents aged 65 and older | Influenza infection | Reduced laboratory-confirmed respiratory viral infections | Wang et al. (2018) |
| Lactobacillus rhamnosus GG | $1 \times 10^9$, via oral | Randomized, double-blind, placebo-controlled study with adults | COVID-19 pneumonia by SARS-CoV-2 | Increased survival rates of patients that received BAT plus oral bacteriotherapy | Ceccarelli et al. (2021) |
| Streptococcus thermophilus DSM 32245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, and Lactobacillus brevis DSM 27961 | $2.4 \times 10^9$, via oral | Retrospective, observational cohort study with adults | | |

In addition, the administration of $L$. rhamnosus GG induces an anti-inflammatory response by increasing the levels of regulatory T cells (Treg) Foxp3+ and decreasing the production of the proinflammatory cytokine IL-6. This anti-inflammatory profile was also observed in mice infected with $P.~aeruginosa$ with intratracheal administration of probiotics $L$. fermentum K.C6.3.1E, $L$. zeae Od.76, and $L$. paracasei ES.D.88, demonstrated by the reduction of lung inflammation and decreased production of IL-6 and tumor necrosis factor (TNF)-α (Fangous et al., 2019).

In an experimental lung infection by $K$. pneumoniae, the administration of viable or inactivated probiotic $Bifidobacterium longum$ 51A induced pulmonary clearance of $K$. pneumoniae by increasing ROS production in alveolar macrophages through activation of the mal/TIRAP signaling pathway (Vieira et al., 2016). There was a concomitant reduction in the inflammatory process and concentration of cytokines TNF-α and IL-6 and an increase in IL-10 in the lungs of mice. However, only viable probiotics were able to increase the levels of IL-10 in the lungs of mice. Viable $B$. longum 51A produces SCFA acetate in large quantities, and acetate administration in mice before respiratory infection by $K$. pneumoniae induced increased production of IL-10 in animals. The authors demonstrated that acetate might be the primary inducer production of IL-10 in this model (Vieira et al., 2016). In addition, intestinal colonization of germ-free mice with $B$. longum 51A restored the ability of these mice to decrease infection by increasing the production of CXCL1 and the recruitment of...
neutrophils (Vieira et al., 2016). In mice infected with IFV, the lower quantity of acetate was also related to increased susceptibility to secondary respiratory pneumococcal infection, mainly due to the impaired bactericidal activity of alveolar macrophages, and this detrimental effect was restored after acetate supplementation (Sencio et al., 2020).

The potential of probiotics to protect the host from pulmonary infections has also been assessed in several clinical studies, including diverse patients, methodological designs, and inclusion criteria (Table 2). Most of these studies focused on probiotics for prevention and treatment of nosocomial pulmonary infections in patients admitted to intensive care units (ICUs). Two prospective, randomized, double-blind, and placebo-controlled studies showed that the probiotics *L. casei rhamnosus* Lcr35 and *L. rhamnosus* GG, administered orally or oropharyngeally, resulted in decreased colonization and infection of the LRT by *P. aeruginosa* or related gram-positive and gram-negative pathogens in patients admitted to the ICU using mechanized pulmonary ventilation (Forester et al., 2008; Morrow et al., 2010). Only one study showed that administration of a synbiotic consisting of *B. breve* Yakult, *L. casei* Shirotia, and galactooligosaccharides decreased the incidence of ventilator-associated pneumonia (VAP) in patients diagnosed with sepsis admitted to the ICU (Shimizu et al., 2018).

In general, we can conclude that the modulation of the intestinal microbiota, mainly with probiotics, is an exciting alternative for treating lung diseases caused by bacteria. Although it is already well established in the literature that probiotic species and strains behave differently according to their metabolic pathways and their interaction with the host, the probiotic species used against lung alterations attract attention to those from the *Lactobacillus* genus. Most articles demonstrated that non-specific immune responses mediated by probiotics, prebiotics, and symbionts are the principal host protection against lung bacteria. Generally, it seemed more significant phagocytic activity of lung macrophages, reduced lung bacterial load, and less tissue inflammation, associated with increased levels of IL-4 and IL-10, increased frequency of Treg cells, increased production of IgA and IgG, and reduced of IL-6 and TNF-α levels. This demonstrates a more resolving anti-inflammatory profile after modulation of the host’s intestinal microbiota. Despite the benefits, these articles use different study designs, experimental models, doses, and routes of administration, making it challenging to translate the results obtained in animal models to humans and thus develop more specific therapies with probiotics.

**Gut-Lung Axis Modulation in the Context of Lung Viral Infections**

Viral infections generally cause common cold, bronchiolitis, and pneumonia and vary widely in severity depending on age, immune and nutritional status, genetics, and use of antibiotics. IFV, RSV, and rhinovirus are the most abundant and common causes of lung infections (Jain, 2017). IFV is well known to cause outbreaks of varying severity every year, but recently the novel coronavirus SARS-CoV-2 has emerged as a pandemic that has caused more than 3.5 million deaths (Zhu et al., 2020) (Table 1).

Several studies have demonstrated the potential for oral and intranasal administration of probiotics such as *L. casei* Shirotia (Yasui et al., 2004), *L. rhamnosus* M21 (Song et al., 2016), *L. pentosus* S-PT84 (Izumo et al., 2010), and *L. plantarum* and *Leuconostoc mesenteroides* (Bae et al., 2018) to protect and increase the survival of IFV-infected animals, mainly by inducing anti-viral immune responses with the activation of NK cells and increased production of cytokines such as IL-12 and IFN-γ, increased production of IgA in the respiratory mucosa, and reduction of polymorphonuclear inflammatory infiltrate in the lung tissue. In addition to these protective effects, *L. rhamnosus* GG administered intranasally (Harata et al., 2010), and *L. acidophilus* L-92 (Goto et al., 2013) also demonstrated the ability to increase the levels of proinflammatory cytokines, such as IL-1β, monocyte chemotactic protein 1 (MCP-1), and chemokines such as eotaxin and M-CSF.

Dendritic cells are crucial for developing immune responses because of their ability to detect pathogens through TLRs and create a link between innate and adaptive immune responses. Mice with depleted alveolar macrophages lost the anti-viral protection against IFV infection conferred by increasing IL-12 and IFN-γ levels after oral administration of the probiotic *L. plantarum* DK119 (Park et al., 2013). In addition, the importance of dendritic cells was demonstrated after oral administration of the probiotic *Lactobacillus lactis* subsp. *lactis* JCM5805 in mice infected with murine parainfluenza virus. The authors showed that the probiotic was incorporated into CD11c+ immune cells in Peyer’s patches and activated plasmacytoid dendritic cells that produce type 1 IFNs at draining mucosal sites. The authors also observed an increase in IFN-related genes, such as *lbg15*, *Oas12*, and *Viperin* in the lungs, suggesting that the type I IFN produced by plasmacytoid dendritic cells could reach systemic levels and induce anti-viral activity in the lungs. In addition, *ex vivo* stimulation with murine parainfluenza virus of lung lymphocytes from mice treated with JCM5805 demonstrated high expression of IFN-α and IFN-β (Jounai et al., 2015).

Determining the taxonomic composition and function of the microbiota is crucial for understanding the impact of probiotics on the protective response against pathogens. The oral administration of *L. paracasei* CNCM I-1518 did not modify the gut microbiota structure in mice infected with IFV; however, it conferred protection against the virus (Belkacem et al., 2017).

Diets rich in inulin and SCFAs improve mouse lung pathology after infection with IFV by promoting the differentiation of alternatively activated macrophages (AAMs) from circulating Ly6C- monocytes and decreasing the immunopathological effects of neutrophils. Also SCFAs increases anti-IFV immunity by enhancing the CD8+ T cells activity by serving as a substrate for fatty acid oxidation and by specifically interacting with the receptor GPR41 (Trompette et al., 2018). One study showed that activation of GPR43 and interferon-α/β receptor (IFNAR) in pulmonary epithelial cells by SCFA acetate induced increased levels of IFN-β in the lungs and increased protection of mice in an experimental model of RSV infection (Antunes et al., 2019).
Other probiotic-derived metabolites also require further investigations. A peptide P18 produced by the probiotic *Bacillus subtilis* 3 (UCM B-5007) share high structural homology with IFV neutralizing antibody, and it is capable of inhibit IFV replication *in vitro* and protect 80% of mice from lethal IFV infection when administered in a therapeutic regimen. This protection is superior to that observed using the anti-viral drug oseltamivir (approximately 70%) (Starosila et al., 2017).

Double-stranded RNA intermediates from IFV and RSV are associated with changes in the host’s coagulation process by activation of receptors such as TLR-3, and retinoic acid-inducible gene I (RIG-I). The activation of these receptors by these viruses, increases the expression of coagulation factors in endothelial cells and monocytes and inhibits fibrinolysis, inducing a prothrombotic state in the hosts, leading to fibrin deposition in the pulmonary alveoli and exacerbation of tissue inflammation. In order to address this issue one study demonstrated in a murine model of IFV and RSV infection, that oral administration of *L. rhamnosus* CRL 1505 in mice increases the clearance of both viruses and controls immune-coagulative responses initiated by the activation of TLR-3 in the lungs, in a process dependent on IL-10 (Zelaya et al., 2014).

Intranasal administration of viable or heat-killed *L. plantarum* NCIMB 8826 and *L. reuteri* F275 protected mice from lethal pneumonia virus of mice (PVM) infection. The lungs showed minimal inflammation, with fewer granulocytes and an increased number of lymphocytes, correlated with a reduction in proinflammatory cytokines CXCL10, CXCL1, CCL2, and TNF-α. Evaluation of the lymphocyte populations demonstrated that treatment did not result in changes in the relative proportions of CD4+ T cells (CD3-CD4+CD8-), CD8+ (CD3-CD4-CD8+), or B cells (B220+). In contrast, the fraction of NK cells (CD3-CD5+) decreased. The authors demonstrated that these results are not specific for *L. plantarum* NCIMB 8826 and *L. reuteri* F275, as the same protection was observed when using the non-pathogenic gram-positive bacteria *Listeria innocua*. These probiotics also increased the survival of mice infected with the PVM, with the deleted MyD88 (TLRs adapter protein) gene (MyD88-/-), thus demonstrating that this induced protection can be TLR-independent (Gabryszewski et al., 2011). However, other studies have determined that the anti-viral activity of probiotics is related to the activation of TLRs. This was demonstrated in mice with *L. rhamnosus* probiotics CRL1505 and CRL1506 that differentially activate the TLR3/RIG-I pathway to inoculate with poly (I:C) (a molecular pattern associated with viruses). The activation of TLR3/RIG-I leads to increased production of IFN-γ, IFN-β, TNF-α, IL-6, and IL-10, the frequency of CD3+CD4+IFN-γ+, CD3+CD4+IL-10+, and the dendritic cells D11cCD11b+CD103+ and CD11c+CD11bhiCD103, in the lungs. Additionally, this study showed an increase in MHC-II levels in both populations of dendritic cells. The authors also demonstrated that this protective response and modulation of the immune response were similar to those observed in mice infected with the human RSV strain (Tomosada et al., 2013).

Clinical studies showed that probiotics have general effects on viral infections of the respiratory tract (Table 2). A randomized, double-blind, placebo-controlled study, on preterm infants showed that a synbiotic composed of *L. rhamnosus* GG ATCC5310 and galactooligosaccharides and polydextrose reduced the rate of rhinovirus infection compared to the placebo group (Luoto et al., 2014). In school-aged children, consumption of *L. brevis* KB290 during the influenza season was associated with a reduction in the clinical diagnosis of IFV infection (Waki et al., 2014). In a randomized, double-blind, placebo-controlled pilot study, the probiotic *L. rhamnosus* GG was also associated with a reduction in the occurrence of influenza infections (Wang et al., 2018).

As demonstrated, the most used probiotics in studies of pulmonary diseases caused by viruses are also those of the *Lactobacillus* genus. The effects of this genus related to increased protection against viruses are linked to increased production of IFN types I and II, proinflammatory cytokines such as IL-12 and IFN-γ, or even increased expression of genes encoding anti-viral factors. Unfortunately, a mechanistic basis for the observed beneficial effects of probiotics in combating viral lung infections is often not well defined. This knowledge gap is mainly because most experiments using probiotics for viral treatment use different study designs and experimental models, doses, times, and routes of administration. Therefore, more research is needed to understand better the role of probiotics in our immune system in fighting viral pulmonary infections.

The Gut-Lung Axis During SARS-CoV-2 Infection

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has spread around the world since 2019 and has been declared a pandemic that continues to spread with devastating consequences to public health. As of July 2021, there were approximately 190, 600, 300 global confirmed cases and 4,130,000 confirmed deaths.

SARS-CoV-2 can invade human cells by binding its spike protein to a variety of receptors, such as angiotensin-converting enzyme 2 (ACE2), neuropilin-1, tyrosine-protein kinase receptor (AXL), and antibody-FcγR complexes (V’kovskii et al., 2021). The current evidence suggests that the severity of COVID-19 is a consequence of a hyperinflammatory immune response culminating in a ‘cytokine storm’, with markedly increased levels of proinflammatory cytokines such as IL-1, IL-6, IL-12, IFN-γ, and TNF-α, which elicit extensive local and systemic tissue damage (Coperchini et al., 2020).

Recent studies have revealed that patients infected with SARS-CoV-2 demonstrate intestinal dysbiosis, which correlates with the susceptibility and severity of COVID-19 (Zuo et al., 2020; Yeoh et al., 2021). Though some studies detected SARS-CoV-2 RNA in the feces of patients, the activity and infectivity of SARS-CoV-2 in the GI tract are still largely unknown (Zuo et al., 2021). However, as ACE2 is highly expressed in the intestinal epithelia, this receptor may be involved in gastrointestinal symptoms that are common in severe cases (Chen et al., 2020; Villapol, 2020; Koester et al., 2021). Interestingly, in a study with gnotobiotic rats, researchers demonstrated that the gut microbiota regulates the colonic mRNA of ACE2 (Yang et al., 2020).
Another study demonstrated that patients with severe COVID-19 had a significant decrease in the abundance of butyrate-producing bacteria, such as Faecalibacterium prausnitzii, Clostridium butyricum, Clostridium leptum, and Eubacterium rectale, and an increased number of common opportunistic pathogens, Enterococcus and Enterobacteriaceae (Tang et al., 2020). In non-human primates infected with SARS-CoV-2, 16S rRNA analysis of the microbial gut community showed changes in the taxonomic composition, with the relative abundance of Acinetobacter and Ruminococcaceae being positively correlated with the presence of SARS-CoV-2 in the URT. In addition, SARS-CoV-2 infection significantly alters the metabolite composition with a reduction in the levels of SCFAs, bile acids, and tryptophan metabolites (Sokol et al., 2021).

The impact of probiotics in COVID-19 and in the cytokine storm can be deduced by their known mechanisms in modulating immune response and inflammation (He et al., 2020; de Oliveira et al., 2021), but more basic and clinical research is needed to show their benefits. In a retrospective study of ICU patients diagnosed with pneumonia caused by SARS-CoV-2, the association of the best available therapy with the probiotics S. thermophilus DSM 32245, B. lactis DSM 32246, B. lactis DSM 32247, L. acidophilus DSM 32241, L. helveticus DSM 32242, L. paracasei DSM 32243, L. plantarum DSM 32244, and L. brevis DSM 27961 showed a positive association with reduced mortality (Ceccarelli et al., 2021).

Gut-Lung Axis Modulation in the Context of Fungal Lung Infections

Among the wide variety of respiratory pathogens, fungi are responsible for only a small proportion of nosocomial or community-acquired pneumonia. However, these species are of relevant medical interest, as fungi cause high morbidity and mortality especially when they affect immunosuppressed patients, or patients with chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) (Charlson et al., 2012; Delhaes et al., 2012).

Although some studies showed that the microbiota in the gut-lung axis is fundamental to the host response to lung infections by fungi, most studies that have demonstrated antimycotic action against respiratory pathogens have been carried out in vitro. In vitro experiments showed that the bacterium Bacillus safensis can block, in a contact-dependent manner, several Cryptococcus neoforms virulence factors including melanin, antiphagocytic capsule, and biofilm formation (Mayer and Kronstad, 2017). Many microorganisms of the genus Bacillus are characterized as probiotics (Hong et al., 2005); however, B. safensis has not yet been characterized as such. B. safensis is phylogenetically close to the prophiotic B. pumilus (Satomi et al., 2006), and its anti-fungal activity has been described (Pandya and Saraf, 2015), making B. safensis an exciting candidate for studies of biological safety and probiotic activity. Another study demonstrated in vitro that treatment with concentrated cell-free supernatant from the culture of L. plantarum 16 altered the transcription of genes involved in a variety of cellular functions, especially those related to cellular metabolism, which culminated in the complete inhibition of spore germination and development of the germ tubes and hyphae of the pathogen A. fumigatus (Crowley et al., 2013). In one in vivo study using the probiotics Saccharomyces boulardii, L. paracasei ST-11, and L. rhamnosus GG, mice were not protected against lung infection caused by the pathogen Cryptococcus gattii (Oliveira et al., 2017).

The recognition of lectins in the fungal cell wall by PRRs is crucial for the activation of dendritic cells and macrophages and the activation of T cells, including Th1 and Th17, which are the best defense strategies against fungal infections, as they help promote the clearance of fungi through innate effectors such as neutrophils and macrophages. The activation of Treg cells and anti-inflammatory cytokines is also fundamental to the anti-fungal immune response, as these cells and molecules are essential for controlling the inflammatory response. The immune response against fungi has already been extensively reviewed by other authors, such as Lionakis et al. (2017).

Among the opportunistic species that affect the lungs, Aspergillus spp. are the primary etiologic agents of invasive lung diseases and mainly affect transplant patients (Kontoyiannis et al., 2010; Pappas et al., 2010). Evidence also suggests that COPD patients are at a high risk of developing invasive aspergillosis, although this association is poorly explored (Hammond et al., 2020). An experimental study demonstrated the importance of intestinal microbiota in structuring the pulmonary anti-Aspergillus immune response. During infection by A. fumigatus, the administration of antibiotics decreased the number of Th17 cells and IL-17 in the lungs, which correlated with a decrease in intestinal colonization by segmented filamentous bacteria (SFB). By investigating how commensal SFBs were linked to this phenotype, the authors, through serum transfer experiments from mice colonized by SFB to negative SFB mice, demonstrated that SFBs contribute to the accumulation of Th17 cells in the lung by inducing an increase in IL-1β. This was confirmed when mice that received serum pre-incubated with an IL-1 antagonist attenuated the response of Th17 cells in the lungs (McAleer et al., 2016). Germ-free mice (GF) infected with C. gattii showed greater susceptibility to lung colonization, mortality, correlated with reduced levels of IFN-γ, IL-1β, and IL-17 and reduced phagocytosis and ROS production than conventional mice. After restoring the intestinal microbiota those mice mounted a stronger response to infection by C. gattii, associated with prolonged survival rates and higher levels of inflammatory mediators (Costa et al., 2016).

Pneumocystis jirovecii is another opportunistic fungus that causes pneumonia, particularly in HIV-positive patients, with an inverse relationship between the CD4+ T cell count in the blood and the risk of infection by P. jirovecii (Dunbar et al., 2020). When investigating the diversity of the intestinal microbial community between immunocompetent mice and mice depleted of CD4+ T cells, with pneumonia caused by Pneumocystis murina, there was a significant change in alpha and beta diversity and a change in the taxonomic abundance of the intestinal microbiota among these groups, suggesting that the loss of CD4+ T cells affects the intestinal microbiota and the response to P. murina. P. murina infection was also found to
increase the expression of genes in the intestinal microbiota related to carbohydrate energy metabolism, xenobiotic degradation, and signal transduction pathways (Samuelson et al., 2016a).

Another study demonstrated that vaccination, using a prime-boost vaccination strategy, with live \textit{P. murina} induced protection against subsequent lung infection with the same pathogen in immunocompetent mice and even in mice depleted of CD4+ T cells. In immunocompetent mice, this immunization increased the number of CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD11b+ macrophages in the lungs after a respiratory infection and increased the levels of IgG and IgA specific for \textit{P. murina}. A significant reduction in the lung load of \textit{P. murina} was observed in serum transfer experiments from non-infected and immunized mice to infected mice. The beta diversity of the intestinal microbial community in mice immunized with \textit{P. murina} was also altered, suggesting that the effectiveness of this immunization may be partly related to the modification of the microbiota; however, further studies are needed to determine whether changes in the microbiota participate in the induction of immunological memory in \textit{P. murina} (Samuelson et al., 2016b).

Despite the importance of the intestinal microbiota and its metabolites for the development of anti-fungal immune responses, and \textit{in vitro} studies demonstrate that probiotics have an action against fungi that cause lung infections, there have been no reports of robust studies aiming to assess the effectiveness of the modulation of \textit{in vivo} intestinal microbiota for the prevention and/or treatment of pulmonary fungal infections. Thus, with the significance of lung infections in mind, more researchers urgently need to turn their attention to this broad and promising field.

**Gut-Lung Axis Modulation in the Context of Parasitic Lung Infection**

Many helminths cause disease, but they have been shown to also influence the pulmonary immune response. Similar to bacteria, they co-evolved with the host’s immune system to maintain a mutually beneficial relationship (Schwartz et al., 2018). Some helminths also share the same niche, the intestinal lumen, with bacteria belonging to the microbiota, and some studies have shown that there are complex interactions between the two (Leung et al., 2018). The intestinal microbiota acts as one of the main inducers of the activation and function of local and systemic antiparasitic responses, such as the activation of Th2 cells and eosinophils (Jiménez-Saiz et al., 2020).

During the larval phase of their life cycle, different species of helminths, such as \textit{Ascaris lumbricoides}, \textit{Toxocara} sp., \textit{Necator americanus}, \textit{Ancylostoma duodenale}, and \textit{Strongyloides} sp., migrate through the lungs and induce pathological immune responses and cause tissue damage, such as eosinophilic pneumonia, which is characterized mainly by increased infiltration of eosinophils in the lung parenchyma and blood eosinophilia (Akuthota and Weller, 2012).

Some studies involving the modulation of the microbiota in spite of helminth infections have focused only on intestinal pathology and on the parasitological aspects of the infection, such as intestinal parasitic load, release of eggs in the feces, and survival of mice. This was demonstrated experimentally with the probiotic \textit{L. casei} ATCC7469 in infection with \textit{Trichinella spiralis} (Bautista-Garfias et al., 2001), \textit{B. animalis} 04450B against infection by \textit{S. venezuelensis} (Oliveira-Sequeira et al., 2014), and \textit{S. boulardii} in mice infected with \textit{T. canis} (Avilada et al., 2012). However, researchers have already reported the beneficial effect of probiotics in reducing the parasitic burden of larval stages during \textit{T. canis} infection in mice. \textit{In vitro} experiments demonstrated a reduction in the viability of \textit{T. canis} larvae after direct incubation with live cells or cell-free supernatant of the probiotic \textit{Enterococcus faecalis} CECT712. The same study also showed that oral administration of \textit{E. faecalis} CECT712 significantly reduced the number of \textit{T. canis} larvae found in the lungs of these animals (Chiodo et al., 2010), \textit{L. rhamnosus} (Walcher et al., 2018) and \textit{L. acidophilus} ATCC 4356 (Cadore et al., 2020) were also able to reduce the parasitic larval burden of \textit{T. canis} in the lungs of mice, but had no antiparasitic action against the larvae \textit{in vitro}, which indicates the indirect action of these two probiotics on \textit{T. canis}, probably related to the stimulation of the protective immune response. The administration of \textit{S. boulardii} in mice infected with \textit{T. canis} increased the transcription of genes encoding IL-12 and IFNγ, which correlated with a decrease in the number of larvae in the lungs and other tissues (de Avila et al., 2016).

Some probiotics, mainly from the \textit{Lactobacillus} genera, showed action \textit{in vitro} and \textit{in vivo} against helminths that cycle through the lungs. However, differences in the efficacy of species and strains used can be attributed to variability in the experimental models, the probiotic dose, and the administration route. However, data are insufficient to determine the molecular mechanisms by which probiotics act on helminths that cycle through the lungs. Furthermore, further studies on host-microbiota-helminth interaction mechanisms are needed to validate the actions of probiotics in clinical studies with humans.

**STUDIES PERSPECTIVES AND CONCLUSION**

Although studies have shown that probiotics, prebiotics, and synbiotics have prophylactic and therapeutic effects against lung infections caused by bacteria, viruses, fungi, and helminths, further studies are needed to better understand the mechanisms of action and molecular pathways involved in these strategies. It is necessary to favor the translational use of gut microbiota modulation strategies as a therapeutic approach to human lung diseases. In addition, since the effect of these strategies is highly linked to the strains of the microorganism and the dose and route of administration, more in-depth investigations should be performed, considering well-defined experimental protocols. Considering the complexity of the microbiota and its interaction with the host, it is also important to determine whether this strategy acts in synergy with the microbiota or has another mechanism involving direct action against the lung pathogen or modulation of the host.
immune system. In addition, it is important to emphasize the therapeutic window necessary to restore the gut microbiota to re-establish homeostasis after lung infection control.

**AUTHOR CONTRIBUTIONS**

CC wrote the manuscript, tables, and made the figures; MR and AV contributed to the design, writing, and review of the manuscript. The authors read and approved the final manuscript.

**REFERENCES**

Akuthota, P., and Weller, P. F. (2012). Eosinophilic Pneumonias. *Clin. Microbiol. Rev.* 25, 649–660. doi:10.1128/CMR.00025-12

Alvarez, S., Herrero, C., Bru, E., and Perdigon, G. (2001). Effect of Lactobacillus Casei and Yogurt Administration on Prevention of *Pseudomonas aeruginosa* Infection in Young Mice. *J. Food Prot.* 64, 1768–1774. doi:10.4315/0362-028X-64.11.1768

Antunes, K. H., Fachi, J. L., de Paula, R., da Silva, E. F., Pral, L. P., dos Santos, A. Á., Alvarez, S., Herrero, C., Bru, E., and Perdigon, G. (2001). Effect of Lactobacillus Paracasei Feeding on the Therapeutic Window Necessary to Restore the Gut Microbiota to Re-establish Homeostasis after Lung Infection Control. *Adv. Nutr.* 11, 979–988. doi:10.1093/ADVANCES/NMAA003

Charlson, E. S., Diamond, J. M., Bittle, K., Fitzgerald, A. S., Yadav, A., Haas, A. R., et al. (2012). Lung-Enriched Organisms and Aberrant Bacterial and Fungal Respiratory Microbiota after Lung Transplant. *Am. J. Respir. Crit. Care Med.* 186, 536–545. doi:10.1164/rccm.201204-0693OC

Chen, R., Yu, Y., Li, W., Liu, Y., Lu, J. X., Chen, F., et al. (2020). Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. *Front. Med. (Lausanne).* 7, 608259–9. doi:10.3389/fmed.2020.608259

Chiappo, P., Spoto, M. D., Pezzani, B. C., Minivielle, M. C., and Basualdo, J. A. (2010). *In Vitro and In Vivo Effects of Enterococcus faecalis CECT77121 on Toxocara Canis.* Mem. Inst. Oswaldo Cruz. 105, 615–620. doi:10.1590/S0074-02762010000500003

Coperochini, F., Chiovato, L., Croce, L., Magri, F., and Rotondi, M. (2020). The Cytokine Storm in COVID-19: An Overview of the Involvement of the Chemokine/Chemokine-Receptor System. *Cytokine Growth Factor Rev.* 53, 25–32. doi:10.1016/j.cytogfr.2020.05.003

Costa, M. C., Santos, J. R., Ribeiro, M. J., Freitas, G. J., Bastos, R. W., Ferreira, G. F., et al. (2016). The Absence of Microbiota Delays the Inflammatory Response to Cryptococcus Gattii. *J. Med. Microbiol.* 65, 187–195. doi:10.1099/jmm.0.608259-0

Dang, A. T., and Marsland, B. J. (2019). Microbes, Metabolites, and the Gut-Lung Axis. *Mucosal Immunol.* 12, 843–850. doi:10.1038/s41385-019-0160-6

De Oliveira, G. L. V., Oliveira, C. N. S., Pinzan, C. F., de Salis, L. V. V., and Cardoso, C. R. D. B. (2021). Microbiota Modulation of the Gut-Lung Axis in COVID-19. *Front. Immunol.* 12, 635471. doi:10.3389/fimmu.2021.635471

Delhaes, L., Monchy, S., Fréalle, E., Hubans, C., Salleron, J., Leroy, S., et al. (2012). The Airway Microbiota in Cystic Fibrosis: A Complex Fungal and Bacterial Community-implications for Therapeutic Management. *PLoS One.* 7, e36313. doi:10.1371/journal.pone.0036313

Dickson, R. P., Erb-Downward, J. R., Freeman, C. M., McCloskey, L., Beck, J. M., Huffnagle, G. B., et al. (2015). Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. *Ann. Am. Thorac. Soc.* 12, 821–300. doi:10.1513/annalsats.201501-029OC

Doron, S., and Snyderman, D. R. (2015). Risk and Safety of Probiotics. *Clin. Infect. Dis.* 60 Suppl 2, S129–S134. doi:10.1093/cid/civ085

Fan, Y., and Pedersen, O. (2021). Gut Microbiota in Human Metabolic Health and Disease. *Nat. Rev. Microbiol.* 19, 55–71. doi:10.1038/s41579-020-0433-9

Fangous, M. S., Alexandre, Y., Hymery, N., Gouriou, S., Arzur, D., Blay, G. L., et al. (2019). Lactobacillus Intra-Tracheal Administration Protects from *Pseudomonas aeruginosa* Infection Intensity of Mice With Toxocariasis. *Vet. Parasitol.* 266, 108056. doi:10.1016/j.vetpar.2020.108056

Funding

This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (402530/2020-9) and (420350/2018-7) to ATV and to CSC Fellowship, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG) (APQ-03328-18), Pro-Reitoria de Pesquisa da Universidade Federal de Minas Gerais -PRPq and Instituto Serrapilheira (Serra-1912-3152).
Response Resulting in Protection from Murine Parainfluenza Virus Infection. PLoS One. 10, e019053–16. doi:10.1371/journal.pone.019053
Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M., and Kim, C. H. (2013). Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice. Gastroenterology 145, 396–406. e10. doi:10.1053/j.gastro.2013.04.056
Koester, S. T., Li, N., Lachance, D. M., Morella, N. M., and Dey, N. (2021). Variability in Digestive and Respiratory Tract Acc2 Expression Is Associated With the Microbiome. PLoS One. 16, e024730–9. doi:10.1371/journal.pone.024730
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaisse, E. J., Walsh, T. J., et al. (2010). Prospective Surveillance for Invasive Fungal Infections in Hemato poetic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50, 1091–1100. e10. doi:10.1086/651263
Köpf, M., Schneider, C., and Nobs, S. P. (2015). The Development and Function of Lung-Resident Macrophages and Dendritic Cells. Nat. Immunol. 16, 36–44. doi:10.1038/ni.3052
Leung, J. M., Graham, A. L., and Knowles, S. C. L. (2018). Parasite-Microbiota Interactions With the Vertebrate Gut: Synthesis Through an Ecological Lens. Front. Microbiol. 9, 843–920. doi:10.3389/fmicb.2018.00843
Li, M., Wang, B., Zhang, M., Rantalaninen, M., Wang, S., Zhou, H., et al. (2008). Symbiotic Gut Microbes Modulate Human Metabolic Phenotypes. Proc. Natl. Acad. Sci. U. S. A. 105, 2117–2122. doi:10.1073/pnas.0710381105
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., and Henricks, P. A. J. (2018). Pro- and Anti-Inflammatory Effects of Short Chain Fatty Acids on Immune and Endothelial Cells. Eur. J. Pharmacol. 831, 52–59. doi:10.1016/j.ejphar.2018.05.003
Limón, J. J., Skalski, J. H., and Underhill, D. M. (2017). Commensal Fungi in Health and Disease. Cell Host Microbe. 22, 156–165. doi:10.1016/j.chom.2017.07.002
Lionakis, M. S., Iliev, I. D., and Hohl, T. M. (2017). Immunity Against Fungi. Fci insight. 2, e01316. doi:10.1172/jci.insight.93156
Luoto, R., Ruuskanen, O., Waris, M., Kalliomäki, M., Salminen, S., and Isolauri, E. (2014). Prebiotic and Probiotic Supplementation Prevents Rhinovirus Infections in Preterm Infants: A Randomized, Placebo-Controlled Trial. J. Allergy Clin. Immunol. 133, 405–413. doi:10.1016/j.jaci.2013.08.020
Marsland, B. J., Trompette, A., and Gollwitzer, E. S. (2015). The Gut-Lung Axis in Respiratory Disease. Ann. Am. Thorac. Soc. 12, S150–S156. doi:10.1513/ AnnalsATS.2015100–33AW
Maslowsky, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., et al. (2009). Regulation of Inflammatory Responses by Gut Microbiota and Chemoattractant Receptor GPR43. Nature 461, 1282–1286. doi:10.1038/ nature08350
Martin, T. R., and Frevert, C. W. (2005). Innate Immunity in the Lungs. Proc. Am. Thorac. Soc. 2, 403–411. doi:10.1513/pats.200508-090oj
Mayer, F. L., and Kronstad, J. W. (2017). Disarming Fungal Pathogens: Bacillus Subtilis Inhibits Virulence Factor Production and Biofilm Formation by Cryptococcus Neoformans and Candida Albicans. MBio. 8, 1–22. doi:10.1128/mBio.01357-17
McAleen, J. P., Nguyen, N. L., Chen, K., Kumar, P., Ricks, D. M., Binnie, M., et al. (2016). Pulmonary Th17 Antifungal Immunity Is Regulated by the Gut Microbiome. J. Immunol. 197, 97–107. doi:10.4049/jimmunol.1502566
Meitert, E., Petrovici, M., Meitert, T., Sima, F., and Costache, G. (2013). Experimental Pseudomonas aeruginosa Pneumonia. Arch. Pathol. Exp. Microbiol. 38, 167–172. doi:10.1097/ SHK.0000000000000066.LACTOBACCILLUS
Morrow, L. E., Kollef, M. H., and Casale, T. B. (2010). Probiotic Prophylaxis of Ventilator-Associated Pneumonia: A Blinded, Randomized, Controlled Trial. Am. J. Respir. Crit. Care Med. 182, 1058–1064. doi:10.1164/rccm.200912-1853OC
Oliveira, L. V. N., Bastos, R. W., Ribeiro, N. Q., Costa, M. C., Acurcio, L. B., Rocha, T. J., et al. (2010). Prospective Surveillance for Invasive Fungal Infections in Hemato poetic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50, 1091–1100. e10. doi:10.1086/651263
Oliveira-Sequeira, T. C. G., David, É. B., Ribeiro, C., Guimarães, S., Masseno, A. P., Katagiri, S., et al. (2014). EFFECT OF Bifidobacterium Animals on MICE INFECTED With Strongyloides venezuelensis. Rev. Inst. Med. Trop. S. Paulo. 56, 105–109. doi:10.1590/S0036-46652014000200003
Jain, S. (2017). Epidemiology of Viral Pneumonia. Clin. Chest Med. 38, 1–9. doi:10.1016/j.ccm.2016.11.012
Jiménez-Saiz, R., Anipindi, V. C., Galipeau, H., Ellenbogen, Y., Chaudhary, R., Koenig, J. F., et al. (2020). Microbial Regulation of Enteric Eosinophils and its Impact on Tissue Remodeling and Th2 Immunity. Front. Immunol. 11, 155. doi:10.3389/fimmu.2020.00155
Jounai, K., Sugimura, T., Ohshio, K., and Fujinawa, D. (2015). Oral Administration of Lactococcus Lactis Subsp. Lactis JCMS5805 Enhances Lung Immune
Lactobacillus Casei Shirota. Clin. Diagn. Lab. Immunol. 11, 675–679. doi:10.1128/CDLI.11.4.675-679.2004
Yazar, A., Atis, S., Konca, K., Pata, C., Akbay, E., Calikoglu, M., et al. (2001). Respiratory Symptoms and Pulmonary Functional Changes in Patients With Irritable Bowel Syndrome. Am. J. Gastroenterol. 96, 1511–1516. doi:10.1016/S0002-9270(01)02311-5
Yeeh, Y. K., Zuo, T., Lui, G. C., Zhang, F., Liu, Q., Li, A. Y., et al. (2021). Gut Microbiota Composition Reflects Disease Severity and Dysfunctional Immune Responses in Patients with COVID-19. Gut. 70, 698–706. doi:10.1136/gutjnl-2020-323020
Zelaya, H., Tsukida, K., Chiba, E., Marranzino, G., Alvarez, S., Kitazawa, H., et al. (2014). Immunobiotic Lactobacilli Reduce Viral-Associated Pulmonary Damage Through the Modulation of Inflammation-Coagulation Interactions. Int. Immunopharmacol. 19, 161–173. doi:10.1016/j.intimp.2013.12.020
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. doi:10.1056/nejmoa2001017
Zuo, T., Liu, Q., Zhang, F., Lui, G. C., Tso, E. Y., Yeoh, Y. K., et al. (2021). Depicting SARS-CoV-2 Faecal Viral Activity in Association with Gut Microbiota Composition in Patients with COVID-19. Gut. 70, 276–284. doi:10.1136/gutjnl-2020-322294
Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., et al. (2020). Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 159, 944–e8. doi:10.1053/j.gastro.2020.05.048

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cruz, Ricci and Vieira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.